Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 2/20 | 0.40 |
| ▸ | AKR1A1 | P14550 | 4/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.40 |
| ▸ | CTSA | P10619 | 5/20 | 0.39 |
| ▸ | KIF11 | P52732 | 5/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3068662 | 0.78 | KDM4E (0.44) | GRIN2BPTGDR2KDM4E | |
| SCHEMBL15007387 | 0.69 | GRM5 (0.62) | GRIN2B | |
| SCHEMBL4453709 | 0.69 | ALDH1A1 (0.46) | CYP19A1KDM4EALDH1A1POLBMAPT | |
| SCHEMBL23448451 | 0.68 | FFAR1 (0.38) | CTSAKDM4EALDH1A1 | |
| SCHEMBL24407601 | 0.67 | PKM (0.40) | GRIN2BCTSAPTGDR2KDM4E | |
| SCHEMBL15025184 | 0.66 | GRM5 (0.57) | ALDH1A1 | |
| SCHEMBL13031308 | 0.65 | CYP19A1 (0.58) | CYP19A1KDM4EALDH1A1POLBMAPT | |
| SCHEMBL24750705 | 0.65 | PKM (0.41) | GRIN2BAKR1A1AKR1B1CTSAPTGDR2 | |
| Trifluoroacetic Acid SCHEMBL3583791 | 0.65 | KDM4E (0.39) | AKR1A1AKR1B1PTGDR2CYP19A1KDM4E | |
| SCHEMBL4778187 | 0.65 | CTSA (0.41) | CTSAKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1368342-B3 | BENZIMIDAZOLE AND PYRIDYLIMIDAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | NEUROGEN CORP (US) | 2010-12-01 | — | — | EP | disclosed |
| US-20100267698-A1 | Benzimidazole and Pyridylimidazole Derivatives | NEUROGEN CORPORATION | 2010-10-21 | — | — | US | disclosed |
| US-7642267-B2 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION (US) | 2010-01-05 | — | — | US | disclosed |
| US-20080227793-A1 | Benzimidazole and Pyridylimidazole Derivatives | NEUROGEN CORPORATION | 2008-09-18 | — | — | US | disclosed |
| US-7300945-B2 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION (US) | 2007-11-27 | — | — | US | disclosed |
| US-20060025425-A1 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION | 2006-02-02 | — | — | US | disclosed |
| EP-1368342-B1 | BENZIMIDAZOLE AND PYRIDYLIMIDAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | NEUROGEN CORP (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6916819-B2 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION (US) | 2005-07-12 | — | — | US | disclosed |
| US-20030069257-A1 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267698-A1 | Benzimidazole and Pyridylimidazole Derivatives | GABBR1, GABBR2, GABRA2 | GRIN2B 111/4885AKR1A1 752/4885AKR1B1 488/4885 |
| US-20080227793-A1 | Benzimidazole and Pyridylimidazole Derivatives | GABBR1, GABBR2, GABRA2 | GRIN2B 111/4885AKR1A1 752/4885AKR1B1 488/4885 |
| US-20060025425-A1 | Benzimidazole and pyridylimidazole derivatives | GABBR1, GABBR2, GABRA2 | GRIN2B 111/4885AKR1A1 752/4885AKR1B1 488/4885 |
| US-20030069257-A1 | Benzimidazole and pyridylimidazole derivatives | GABBR1, GABRA1, GABBR2 | GRIN2B 158/4885AKR1A1 402/4885AKR1B1 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.